Pure Global
NCT05548764

Prevention Bundles for SSIs (PREBUSSI).

Prevention Bundles for Surgical Site Infections (PREBUSSI): a Multi-center Observational Study.
Maximos Frountzas·ClinicalTrials.gov·procedureNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Surgical Site Infection
Drug/Device/Intervention
Prevention Bundles for SSIs
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
Maximos Frountzas
Funder
National and Kapodistrian University of Athens
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2022
End date
Dec 30, 2023
Enrollment
200 participants
Primary outcome

Incidence of SSIs

Summary

Surgical site infections (SSIs) are the most complication after a surgical operation and
 their incidence reaches 20% worldwide. SSIs have been associated to significant morbidity and
 mortality, high ICU admission rates, increased length of hospital stay, high readmission
 rates and raised cost. However, there is no registry for SSIs in Greece so far. In addition,
 it has been considered that almost half of SSIs could be prevented. Therefore, several
 prevention strategies have been suggested by international health organizations, such as WHO
 and NICE, that seem to be effective. The aim of the present study is to investigate the
 effect of 10 prevention bundles on the rate of SSIs, as well their consequences on several
 financial parameters of the Greek healthcare system.

ICD-10 classifications
Infection following a procedure, not elsewhere classifiedBacterial infection of unspecified siteOther bacterial infections of unspecified siteInfection of obstetric surgical woundOther specified local infections of skin and subcutaneous tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05548764
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05548764 through Pure Global AI's free database. This phase not specified trial is sponsored by Maximos Frountzas and is currently Not yet recruiting. The study focuses on Surgical Site Infection. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.